Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and design overview

Clinical Journal of the American Society of Nephrology

Volumn 2, Issue 5, 2007, Pages 898-905

  Chertow, Glenn M ^a   Pupim, Lara B ^b   Block, Geoffrey A ^c   Correa Rotter, Ricardo ^d   Drueke, Tilman B ^e   Floege, Jürgen ^f   Goodman, William G ^a,g   London, Gerard M ^h   Mahaffey, Kenneth W ⁱ   Moe, Sharon M ^j   Wheeler, David C ^k   Albizem, Moetaz ^b   Olson, Kurt ^b   Klassen, Preston ^b   Parfrey, Patrick ^l  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AMGEN INC   (United States)

^c Denver Nephrologists   (United States)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Hopital Manhes   (France)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^l MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CINACALCET; NAPHTHALENE DERIVATIVE;

ARTICLE; CARDIOVASCULAR DISEASE; DOUBLE BLIND PROCEDURE; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SECONDARY HYPERPARATHYROIDISM;

CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; HUMANS; HYPERPARATHYROIDISM, SECONDARY; NAPHTHALENES; RANDOMIZED CONTROLLED TRIALS; RENAL DIALYSIS;

EID: 34548821615     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04381206     Document Type: Article

References (27)

1. USRDS: the United States Renal Data System. Am J Kidney Dis 42: 1-230, 2003
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW; American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42: 1050-1065, 2003
3. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
4. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
5. Cheung AK, Levin NW, Greene T, Agodoa L, Bailey J, Beck G, Clark W, Levey AS, Leypoldt JK, Ornt DB, Rocco MV, Schulman G, Schwab S, Teehan B, Eknoyan G: Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. J Am Soc Nephrol 14: 3251-3263, 2003
6. Abdelfatah AB, Motte G, Ducloux D, Chalopin JM: Determinants of mean arterial pressure and pulse pressure in chronic haemodialysis patients. J Hum Hypertens 15: 775-779, 2001
7. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478 -1483, 2000
8. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato JA, Szczech LA, Lazarus JM, Owen WF: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287: 1548-1555, 2002
9. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
10. Young EW, Akiba T, Albert JM, McCarthy JT, Kerr PG, Mendelssohn DC, Jadoul M: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 44: 34-38, 2004
11. Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 study. J Am Soc Nephrol 16: 1788-1793, 2005
12. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
13. Martinez I, Saracho R, Montenegro J, Llach F: The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 29: 496-502, 1997
14. Coburn JW, Maung HM: Calcimimetic agents and the calcium-sensing receptor. Curr Opin Nephrol Hypertens 9: 123-132, 2000
15. Cundy T, Hand DJ, Oliver DO, Woods CG, Wright FW, Kanis JA: Who gets renal bone disease before beginning dialysis? BMJ (Clin Res Ed) 290: 271-275, 1985
16. Spasovski GB, Bervoets AR, Behets GJ, Ivanovski N, Sikole A, Dams G, Couttenye MM, De Broe ME, D'Haese PC: Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant 18: 1159-1166, 2003
17. Coen G, Mazzaferro S, Ballanti P, Sardella D, Chicca S, Manni M, Bonucci E, Taggi F: Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant 11: 813-819, 1996
18. Suzuki T, Yonemura K, Maruyama Y, Takahashi T, Takita T, Furuhashi M, Hishida A: Impact of serum parathyroid hormone concentration and its regulatory factors on arterial stiffness in patients undergoing maintenance hemodialysis. Blood Purif 22: 293-297, 2004
19. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: A longitudinal study. Kidney Int 70: 351-357, 2006
20. Brown EM, MacLeod RJ: Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev 81: 239-297, 2001
21. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004
22. Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW: Cinacalcet HC1, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800-807, 2005
23. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM: Effects of the calcimimetic cinacalcet HC1 on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68: 1793-1800, 2005
24. NKF-K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-S201, 2003
25. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523-534, 2003
26. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators: Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567-1577, 2006
27. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32[Suppl 3]: S112-S119, 1998